Andrew M Tan

11PUBLICATIONS
12CO-AUTHORS
Environmental rehabilitation and restorationAutonomic nervous systemToxicology (incl. clinical toxicology)Molecular medicinePharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 04, 2026
Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation.

|Dec 31, 2025
Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases.

Noga Gershoni Emek, Andrew M Tan, Michal Geva

|Sep 05, 2025
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Ralf Reilmann, Andrew Feigin, Anne E Rosser

|Mar 18, 2025
Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis.

Michal Geva, Y Paul Goldberg, Henk Schuring

|Mar 07, 2025
The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington's Disease.

Yigal Paul Goldberg, Leehee Navon-Perry, Andrés Cruz-Herranz

|Feb 20, 2025
Antidopaminergic medications in Huntington's disease.

Andrew M Tan, Michal Geva, Y Paul Goldberg

Pageof 2

Frequent Collaborators

2 joint publications

Stephen G Waxman

1 joint publications

Curtis A Benson

1 joint publications

Sierra D Kauer

1 joint publications

Afrin A Tarafder